Immunoglobulin News and Research

RSS

Heat Biologics SARS-CoV-2 vaccine generates potent T cell response in pre-clinical trial

The COVID-19 pandemic is still creating economic and health-related impact over the world. A new study published on the preprint server bioRxiv in August 2020 shows that a gp96-Ig-secreting vaccine candidate based on the expression of full-length spike protein generates a potent T cell response.

26 Aug 2020

Identifying COVID-19 host genes using symptom-based predictions

A recent study published on the preprint server bioRxiv* in August 2020 shows that symptom-based prediction of the diagnosis can help identify host genes that are responsible for part of this variability.

26 Aug 2020

Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.

25 Aug 2020

High SARS-CoV-2 antibody seroprevalence, low mortality at Austrian COVID-19 epicenter

Now, a new study reported on the preprint server medRxiv* in August 2020 describes a high seroprevalence in an Austrian ski resort, which is considered to be the source of the European outbreak.

25 Aug 2020

Study reveals protective potential of all three major immunoglobulin isotypes against SARS-CoV-2

In a recent medRxiv preprint paper, researchers from Mount Sinai in New York showed that all three major immunoglobulin isotypes (IgM, IgG, and IgA) produced by our immune cells were capable of mediating neutralization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, neutralization titers correlated much better with binding levels of IgM and IgA1 than IgG.

24 Aug 2020

DNA nanoswitches may provide an inexpensive platform to rapidly detect emerging viruses

Programmable DNA nanoswitches that bind to viral RNA in human body fluids may provide an inexpensive platform to rapidly detect a wide variety of emerging viruses, including SARS-CoV-2, according to a new study.

21 Aug 2020

Macaques show low neutralizing antibody and cellular immune response to SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 presents a cynomolgus macaque model that develops symptomatic SARS-CoV-2 infection in a mild form, with low or no antibody responses, making it suitable to study human responses to vaccines and drugs targeting the virus.

21 Aug 2020

New SARS-CoV-2 vaccine effective in macaques

Researchers from the biotechnology company Novavax in Gaithersburg, Maryland, have developed a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that successfully induces immunogenicity and protection against the virus in macaques.

20 Aug 2020

Combination treatment can benefit children with Kawasaki disease

Adding corticosteroids to standard intravenous (IV) immunoglobulin treatment for children with Kawasaki disease judged to be at higher risk of developing blood vessel complications made initial treatment more successful and prevented these complications.

19 Aug 2020

Gut microbiome may play a part in severe COVID-19

A recent study published on the preprint medRxiv* in August 2020 reports on the evidence that the gut microbiome may play a part in severe COVID-19 infection.

19 Aug 2020

COVID immunity related to how bad you get it

Researchers at Stanford University in California have shown that severely ill patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection develop significantly higher levels of antibodies against the virus than asymptomatic individuals and outpatients.

18 Aug 2020

Absolute Antibody offers SARS-CoV-2 neutralizing antibodies derived from COVID-19 patients

Absolute Antibody Ltd. today announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19.

From Absolute Antibody Ltd 18 Aug 2020

Majority of recovered COVID-19 patients have low neutralizing antibody titers

Now, a new study by researchers at New York University and published on the preprint server bioRxiv* in August 2020 reports on the type and intensity of anti-SARS-CoV-2 antibodies in recovered COVID-19 patients and the implications of these findings.

18 Aug 2020

Pre-COVID-19 coronavirus immunity does not protect against SARS-CoV-2

A recent study by researchers in France that's currently available on the medRxiv* preprint server claims that having previous immunity against common coronaviruses (alpha and beta) cannot protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Aug 2020

Scientists claim signs of lasting SARS-CoV-2 immunity

Questions have been raised by many health experts on whether being infected with SARS-CoV-2 brings lasting immunity. Now, scientists have uncovered signs of strong and lasting immunity in people who even had a mild illness of COVID-19.

17 Aug 2020

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

SARS-CoV-2 infection and transmission possible in North American deer mice

The current COVID-19 pandemic began as a zoonosis in China, at the end of 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel betacoronavirus with significant similarity to an earlier virus of the same family.

11 Aug 2020

Only half of pregnant women worldwide get treatment for preventable Rh disease

Only half of pregnant women worldwide who need a treatment developed over 50 years ago to prevent Rh disease--an often-fatal condition in fetuses and newborns that is now exceedingly rare in the United States and Western Europe--actually receive it, finds a study led by researchers at Vagelos College of Physicians and Surgeons at Columbia University Irving Medical Center.

10 Aug 2020

Evidence for antibody longevity in COVID-19 patients

A study led by researchers at the University of Toronto, Canada, has found evidence that immunoglobulin G (IgG) antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are sustained for at least three months.

5 Aug 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020